Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Molecular Test Identifies Sepsis Patients Most Likely to Have Positive Blood Cultures

By LabMedica International staff writers
Posted on 17 Feb 2026

Sepsis is caused by a patient’s overwhelming immune response to an infection. More...

If undetected or left untreated, sepsis leads to tissue damage, organ failure, permanent disability, and often death. Around the world, physicians struggle to rapidly and reliably identify sepsis due to the lack of adequate diagnostic tools. Blood cultures remain a cornerstone of sepsis management, yet are frequently negative, delayed, or contaminated. Now, new study findings highlight a strong association between a patient's sepsis risk and likelihood of positive cultures, with a molecular test delivering results just 90 minutes after a blood draw.

Immunexpress (Brisbane, Australia) pioneers technology that rapidly detects sepsis by analyzing the patient's immune response, marking a paradigm shift away from traditional pathogen-detection methods. The company’s SeptiCyte RAPID is a sample-to-answer, cartridge-based, host response molecular test for sepsis using reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression of two host response genes (PLAC8 and PLA2G7) from whole blood.

SeptiCyte RAPID generates a SeptiScore within approximately one hour, reported across four interpretation bands reflecting increasing likelihood of sepsis. SeptiCyte RAPID runs on the Biocartis Idylla platform and is intended for use in conjunction with clinical assessments, vital signs, and other laboratory findings as an aid in differentiating infection-positive sepsis from non-infectious systemic inflammation.

The latest study was a post-hoc retrospective analysis of data from three prospective observational cohorts encompassing North America, Europe, and sub-Saharan Africa. The analysis included 506 critically ill and acute care patients, with sepsis independently adjudicated and blinded to SeptiCyte RAPID results.

The findings, published in Journal of Clinical Medicine, show that higher SeptiScores were strongly associated with blood culture positivity, with >90% of blood culture–positive sepsis patients falling into the highest SeptiScore bands. No blood culture–positive sepsis cases were observed in the lowest SeptiScore band, highlighting the test' ability to identify patients at very low likelihood of sepsis.

Diagnostic performance was strong, with an AUC of 0.91 for distinguishing blood culture–positive sepsis from non-infectious systemic inflammation (SIRS). Importantly, binary cut-point analyses demonstrated 100% sensitivity at low SeptiScores (<5.0) and 100% specificity at high SeptiScores (>11.4) within this dataset, underscoring the potential clinical utility of SeptiCyte RAPID as an early risk-stratification tool.

"The study findings suggest that SeptiCyte RAPID, when used alongside clinical assessment, may help clinicians prioritize which patients are most likely to benefit from blood cultures, interpret equivocal results, and potentially reduce unnecessary testing," stated Dr. Maik von der Forst from the Heidelberg University Hospital Germany. "There is a need for tools that guide the use of microbiologic diagnostics in the hospital and especially in resource-constrained healthcare settings, emergency departments, and ICUs."

Related Links:
Immunexpress 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.